Amgen (AMGN) is terminating its license and collaboration agreement with Japan-based Kyowa Kirin relating to the research, development, and commercialization of rocatinlimab, a potential treatment for moderate to severe atopic dermatitis, the company said in a regulatory filing Friday.
The agreement, signed in 2021, will be effectively terminated upon regulatory approval, the company said.
Price: 339.63, Change: -3.31, Percent Change: -0.97
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments